1
|
Wang ZZ, Wu PF, Yue HY, Gao X, Ma YY, Ma YY, Guo XR, Zhang HP. Electrochemical Determination of Levodopa Using Zinc Sulfide Nanospheres-Reduced Graphene Oxide. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY 2021; 21:5666-5672. [PMID: 33980378 DOI: 10.1166/jnn.2021.19486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Zinc sulfide nanospheres (ZnS NSs) were prepared by hydrothermal synthesis and graphene oxide (GO) was prepared by the Hummer's method. ZnS NSs-rGO/ITO electrode was synthesized by heat treatment at a certain temperature, which was used for the detailed electrochemical determination of levodopa (LD). Finally, they were annealed to form the ZnS NSs-rGO/ITO electrode for detecting levodopa (LD). The results reveal that the ZnS NSs with the diameter of ~1 μm are covered by rGO. The ZnS NSs-rGO/ITO electrode has a good sensitivity of 1.43 μA μM -1 for the determination of LD in the concentration range of 1-40 μM. Moreover, it also shows a good selectivity, reproducibility and stability. In order to verify the practicability, we also use the electrode to detect LD in human serum. The detection results also prove that the electrode can be used in real life.
Collapse
Affiliation(s)
| | - P F Wu
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - H Y Yue
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - X Gao
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - Y Y Ma
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - Y Y Ma
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - X R Guo
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| | - H P Zhang
- School of Materials Science and Engineering, Harbin University of Science and Technology, Harbin 150040, People's Republic of China
| |
Collapse
|
2
|
Mohite GM, Dwivedi S, Das S, Kumar R, Paluri S, Mehra S, Ruhela N, S A, Jha NN, Maji SK. Parkinson's Disease Associated α-Synuclein Familial Mutants Promote Dopaminergic Neuronal Death in Drosophila melanogaster. ACS Chem Neurosci 2018; 9:2628-2638. [PMID: 29906099 DOI: 10.1021/acschemneuro.8b00107] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
α-Synuclein (α-Syn) aggregation and amyloid formation are associated with loss of dopaminergic neurons in Parkinson's disease (PD). In addition, familial mutations in α-Syn are shown to be one of the definite causes of PD. Here we have extensively studied familial PD associated α-Syn G51D, H50Q, and E46K mutations using Drosophila model system. Our data showed that flies expressing α-Syn familial mutants have a shorter lifespan and exhibit more climbing defects compared to wild-type (WT) flies in an age-dependent manner. The immunofluorescence studies of the brain from the old flies showed more dopaminergic neuronal cell death in all mutants compared to WT. This adverse effect of α-Syn familial mutations is highly correlated with the sustained population of oligomer production and retention in mutant flies. Furthermore, this was supported by our in vitro studies, where significantly higher amount of oligomer was observed in mutants compared to WT. The data suggest that the sustained population of oligomer formation and retention could be a major cause of cell death in α-Syn familial mutants.
Collapse
Affiliation(s)
- Ganesh M. Mohite
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Saumya Dwivedi
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Subhadeep Das
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
- IITB-Monash Research Academy, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Rakesh Kumar
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Sravya Paluri
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Surabhi Mehra
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Neha Ruhela
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Arunima S
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Narendra Nath Jha
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| | - Samir K. Maji
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
| |
Collapse
|
3
|
Hudry J, Rinne JO, Keränen T, Eckert L, Cochran JM. Cost-Utility Model of Rasagiline in the Treatment of Advanced Parkinson's Disease in Finland. Ann Pharmacother 2016; 40:651-7. [PMID: 16569799 DOI: 10.1345/aph.1g454] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background: The economic burden of Parkinson's disease (PD) is high, especially in patients experiencing motor fluctuations. Rasagiline has demonstrated efficacy against symptoms of PD in early and advanced stages of the disease. Objective: To assess the cost-utility of rasagiline and entacapone as adjunctive therapies to levodopa versus standard levodopa care in PD patients with motor fluctuations in Finland. Methods: A 2 year probabilistic Markov model with 3 health states: “25% or less off-time/day,” “greater than 25% off-time/day,” and “dead” was used. Off-time represents time awake with poor or absent motor function. Model inputs included transition probabilities from randomized clinical trials, utilities from a preference measurement study, and costs and resources from a Finnish cost-of-illness study. Effectiveness measures were quality-adjusted life years (QALYs) and number of months spent with 25% or less off-time/day. Uncertainty around parameters was taken into account by Monte Carlo simulations. Results: Over 2 years from a societal perspective, rasagiline or entacapone as adjunctive therapies to levodopa showed greater effectiveness than levodopa alone at no additional costs. Benefits after 2 years were 0.13 (95% CI 0.08 to 0.17) additional QALYs and 5.2 (3.6 to 6.7) additional months for rasagiline and 0.12 (0.08 to 0.17) QALYs and 5.1 (3.5 to 6.6) months for entacapone, both in adjunct to levodopa compared with levodopa alone. Conclusions: The results of this study support the use of rasagiline and entacapone as adjunctive cost-effective alternatives to levodopa alone in PD patients with motor fluctuations in Finland. With a different mode of action, rasagiline is a valuable therapeutic alternative to entacapone at no additional charge to society.
Collapse
Affiliation(s)
- Joumana Hudry
- International Department of Health Economics and Epidemiology, H Lundbeck A/S, Paris, France.
| | | | | | | | | |
Collapse
|
4
|
Hechtner MC, Vogt T, Zöllner Y, Schröder S, Sauer JB, Binder H, Singer S, Mikolajczyk R. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 2014; 20:969-74. [DOI: 10.1016/j.parkreldis.2014.06.001] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 05/21/2014] [Accepted: 06/01/2014] [Indexed: 10/25/2022]
|
5
|
Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005; 192:73-8. [PMID: 15698620 DOI: 10.1016/j.expneurol.2004.11.013] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2004] [Revised: 11/05/2004] [Accepted: 11/10/2004] [Indexed: 10/25/2022]
Abstract
Levodopa or short-acting dopamine (DA) agonist treatment of advanced parkinsonian patients exposes striatal DA receptors to non-physiologic intermittent stimulation that contributes to the development of dyskinesias and other motor complications. To determine whether continuous dopaminergic stimulation can delay or prevent onset of motor complications, four MPTP-lesioned, levodopa-naive cynomolgus monkeys were implanted subcutaneously with apomorphine containing ethylene vinyl acetate rods. Three other MPTP-lesioned monkeys received daily injections of apomorphine. Animals receiving apomorphine rods showed improved motor function ('ON' state) within 1 day of implantation, and remained continually 'ON' for the duration of treatment (up to 6 months) without developing dyskinesias. Injected animals also showed similar improvement in motor function after each apomorphine injection. However, these primates remained 'ON' for only 90 min and within 7-10 days all developed severe dyskinesias. Implanted monkeys evidenced local irritation, which was alleviated by steroid co-therapy.
Collapse
Affiliation(s)
- Francesco Bibbiani
- Experimental Therapeutic Branch, Building 10, Room 5C103, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892-1406, USA
| | | | | | | |
Collapse
|